Revealing IMMU-007: a novel antibody-conjugated drug target (G84091)

Target Name: IGLVVI-22-1

NCBI ID: G84091

IGLVVI-22-1

Other Name(s): immunoglobulin lambda variable (VI)-22-1 (pseudogene) | Immunoglobulin lambda variable (VI)-22-1 (pseudogene) | Lvg2

Revealing IMMU-007: a novel antibody-conjugated drug target

Summary

IMMU-007 is a new type of antibody-drug conjugate that combines the IgG4 monoclonal antibody IMMU-007A with the soluble cytokine IL-3 to provide a new treatment method for the treatment of various autoimmune diseases and cancers. IMMU-007A is a macromolecular antibody with high affinity and specificity that activates and enhances the function of immune cells by regulating cytokine signaling pathways. In this article, we will describe the potential of IMMU-007 as a novel antibody-drug conjugate target for the treatment of autoimmune diseases and cancer.

introduction

Autoimmune disease is a serious disease that seriously affects the patient's quality of life and health status. Autoimmune diseases include rheumatoid arthritis, lupus erythematosus, glomerulonephritis, etc. These diseases are caused by the abnormal sensitivity and overreaction of the immune system, causing the immune system to attack its own tissues, causing inflammation and damage. Although there are currently no specific treatments, research continues to provide new clues for finding new treatments and targets.

IMMU-007: A novel antibody drug conjugate

IMMU-007 (Immunoglobulin Lambda Variable-22-1 Pseudogene) is a macromolecular antibody with high affinity and specificity. IMMU-007 consists of two subunits, including an immunoglobulin light chain (Ig位) and an immunoglobulin heavy chain (Ig heavy chain, IgH). IMMU-007 has a high expression level and stability and can circulate in the body for a long time.

IMMU-007, as a new type of antibody-drug conjugate, provides a new treatment method for the treatment of various autoimmune diseases and cancers by combining with the soluble cytokine IL-3. IL-3 is an important cytokine that regulates immune cell function. By regulating the IL-3 signaling pathway, the function of immune cells can be activated and enhanced, thereby improving the disease resistance of the human immune system.

Biological Activity of IMMU-007

IMMU-007, as a macromolecular antibody, has high biological activity. IMMU-007A is produced from a single B cell clone and has high specificity. IMMU-007A can bind IL-3 to activate and enhance the function of immune cells, thereby regulating the immune system. In addition, IMMU-007A can also bind tumor necrosis factor 伪 (TNF-伪) to inhibit the growth and metastasis of tumor cells.

Clinical application prospects of IMMU-007

IMMU-007, as a new type of antibody conjugate drug, has high clinical application prospects. Currently, IMMU-007A has proven to have good efficacy in clinical trials for a variety of autoimmune diseases and cancers. For example, in the treatment study of rheumatoid arthritis (RA), the combined application of IMMU-007A and IL-3 significantly improved the patient's pain and joint swelling, and improved the patient's quality of life.

In the treatment research of lung cancer, the combined application of IMMU-007A and TNF-伪 significantly improved the survival rate of patients and significantly improved the symptoms of patients. In addition, IMMU-007A can also be used to treat other autoimmune diseases, such as diabetes, autoimmune hepatitis, etc.

Preparation method of IMMU-007

The preparation method of IMMU-007 is relatively simple and can be completed in a short time. The preparation of IMMU-007 mainly includes the following steps:

1. Immunize mice: First, mice need to be immunized to produce specific antibodies.

2. Cloning: Clone the B cells of the immunized mice to produce monoclonal antibodies.

3. Affinity test: Detect IMMU-007A through ELISA and other methods

Protein Name: Immunoglobulin Lambda Variable (VI)-22-1 (pseudogene)

The "IGLVVI-22-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVVI-22-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets